Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine PET Occupancy in Depression
NCT06026917Phase 4Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Sep 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Primary endpoint: Percentage of Dopamine Transporters Occupancy in the Basal Ganglia at Day 42. Status: unknown.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06026917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026917.